Organ rejection prophylaxis:
Indications for: PROGRAF INJECTION
Organ rejection prophylaxis in patients with allogeneic kidney, liver, heart, or lung transplants, in combination with other immunosuppressants.
Give at least 6hrs after transplantation if unable to tolerate oral caps. Heart: initially 0.01mg/kg/day. Liver or kidney: initially 0.03–0.05mg/kg/day. Lung: initially 0.01–0.03mg/kg/day. All: give by continuous IV infusion until oral caps can be tolerated. Monitor at least the first 30mins of infusion and at frequent intervals thereafter. Concomitant corticosteroid is recommended early post-transplantation. Renal or hepatic impairment: use lowest effective dose. Post-op oliguria: give initial dose no sooner than 6hrs and within 48hrs of transplantation, but may be delayed until renal function recovers. See full labeling.
Give at least 6hrs after transplantation if unable to tolerate oral forms. Liver: initially 0.03–0.05mg/kg/day by continuous IV infusion until oral forms can be tolerated. Monitor at least the first 30mins of infusion and at frequent intervals thereafter.
Malignancies. Serious infections.
PROGRAF INJECTION Warnings/Precautions:
Increased risk of lymphomas and other malignancies (eg, skin) due to immunosuppression. Avoid sun, UV light. Increased risk of infections (eg, bacterial, viral, fungal, protozoal), including opportunistic infections. Monitor Epstein-Barr virus serology, development of infections during therapy. Oral forms are not interchangeable with other tacrolimus ext-rel products. Only physicians experienced in immunosuppressive therapy should prescribe Prograf. Risk of new onset diabetes after transplant (esp. Hispanic and black patients); monitor blood glucose. Hepatic or renal impairment; monitor and consider dose reduction. Obtain tacrolimus whole blood concentrations, serum creatinine, serum potassium, and fasting glucose periodically. Monitor and control BP. Avoid in congenital long QT syndrome. CHF, bradyarrhythmias, concomitant antiarrhythmic drugs, or electrolyte disturbances; consider obtaining ECGs and monitor electrolytes periodically. Discontinue or reduce dose if myocardial hypertrophy occurs. Thrombotic microangiopathy (including hemolytic uremic syndrome and thrombotic thrombocytopenic purpura) esp. in those with severe infections, GVHD, HLA mismatch. Complete required immunizations prior to transplantation and treatment. IV: have epinephrine readily available. Elderly. Labor & delivery. Advise females and males of reproductive potential to use appropriate contraception prior to initiation. Pregnancy. Nursing mothers.
PROGRAF INJECTION Classification:
PROGRAF INJECTION Interactions:
Concomitant sirolimus (in liver/heart transplant), live vaccines: not recommended. Concomitant mTOR inhibitors (eg, sirolimus, everolimus) may increase risk of thrombotic microangiopathy. Concomitant strong CYP3A4 inhibitors/inducers or substrates: must adjust dosing regimen, closely monitor tacrolimus blood concentrations and for QT prolongation. Caution with mycophenolic acid; reduce dose of these as needed. Caution with potassium-sparing diuretics, ACEIs, ARBs. Avoid grapefruit or grapefruit juice. Additive nephrotoxicity with cyclosporine (discontinue at least 24hrs prior to initiating the other drug), aminoglycosides, ganciclovir, amphotericin B, cisplatin, NRTIs, protease inhibitors; if concomitant use, monitor renal function and tacrolimus blood levels; adjust doses of both drugs. May be potentiated by calcium channel blockers (eg, verapamil, diltiazem, nifedipine), antifungals (eg, voriconazole, posaconazole, itraconazole, fluconazole, ketoconazole), macrolides (eg, troleandomycin, clarithromycin, erythromycin), lansoprazole, omeprazole, chloramphenicol, cimetidine, cyclosporine, amiodarone, danazol, ethinyl estradiol, protease inhibitors (eg, nelfinavir, telaprevir, boceprevir, ritonavir), nefazodone, letermovir, schisandra sphenanthera extract, magnesium-aluminum-hydroxide, metoclopramide. May be antagonized by carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St. Johns wort, methylprednisolone, prednisone, caspofungin. Monitor closely with direct acting antiviral therapy; may need to adjust dose.
Tremor, headache, constipation, diarrhea, nausea, abdominal pain, insomnia, hypertension, renal dysfunction, fever, serious viral infections (eg, CMV, PML, PVAN), leukopenia, anemia, bronchitis, pericardial effusion, UTI, paresthesia, peripheral edema, hyperkalemia, hypomagnesemia, hyperlipidemia, hyperglycemia; nephrotoxicity or neurotoxicity (esp. in high doses), diabetes mellitus, posterior reversible encephalopathy syndrome (consider reduced dose or discontinue), malignancies (eg, lymphomas, skin), post-transplant lymphoproliferative disorder, myocardial hypertrophy, pure red cell aplasia, Torsade de Pointes; IV: anaphylaxis (monitor and discontinue if occurs).
Oral administration: Fecal (92.6 ± 30.7%), renal (2.3 ± 1.1%). Half-life: 31.9 ± 10.5 hours based on radioactivity; 48.4 ± 12.3 hours based on tacrolimus concentrations.
Generic Drug Availability:
Caps—100; Granules—50; Ampules—10